Meeder Asset Management’s Alaunos Therapeutics TCRT Stock Holding History

Meeder Asset Management’s Portfolio TCRT Stock Details TCRT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-4	Closed	-$82	–	565
2023 Q3	$82	Sell	4 -29	-88%	-$1.25K	﹤0.01%	478
2023 Q2	$2.5K	Hold	33	–	–	﹤0.01%	477
2023 Q1	$3.09K	Sell	33 -34	-51%	-$3.24K	﹤0.01%	545
2022 Q4	$6.49K	Sell	67 -26	-28%	-$3.77K	﹤0.01%	685
2022 Q3	$24K	Hold	93	–	–	﹤0.01%	1052
2022 Q2	$17K	Sell	93 -8	-8%	-$765	﹤0.01%	1207
2022 Q1	$9K	Buy	+101	New	+$13K	﹤0.01%	1598
2021 Q4	–	Sell	-36	Closed	-$10K	–	2217
2021 Q3	$10K	Hold	36	–	–	﹤0.01%	1672
2021 Q2	$14K	Hold	36	–	–	﹤0.01%	1592
2021 Q1	$19K	Buy	+36	New	+$22.4K	﹤0.01%	1425
2020 Q4	–	Sell	-49	Closed	-$19K	–	2207
2020 Q3	$19K	Buy	+49	New	+$21.6K	﹤0.01%	1188
2019 Q1	–	Sell	-4	Closed	-$1K	–	1845
2018 Q4	$1K	Hold	4	–	–	﹤0.01%	1652
2018 Q3	$2K	Buy	+4	New	+$1.72K	﹤0.01%	1445
2017 Q2	–	Sell	-15	Closed	-$15K	–	1865
2017 Q1	$15K	Sell	15 -5	-25%	-$4.66K	﹤0.01%	770
2016 Q4	$16K	Buy	+20	New	+$18K	﹤0.01%	684

Other funds holding TCRT

MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DCM

Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MCA

Magnolia Capital Advisors Jackson, Mississippi $509M AUM 18.99% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

Meeder Asset Management's TCRT Position: Q4 2023 in Review

Meeder Asset Management sold out of Alaunos Therapeutics (TCRT) in Q4 2023, closing a stake of 4 shares — an estimated $82 sold.

Meeder Asset Management first reported a position in TCRT in Q4 2016 and held it in 15 quarters. The position peaked at $24K in Q3 2022. 82 funds tracked by Wall St. Rank hold TCRT as of Q4 2023.

Meeder Asset Management reported no remaining Alaunos Therapeutics position as of Q4 2023 after selling out during the quarter.
Meeder Asset Management sold 4 Alaunos Therapeutics shares in Q4 2023, an estimated $82.
Meeder Asset Management first reported a position in Alaunos Therapeutics in Q4 2016 and held it in 15 quarters.
Meeder Asset Management's Alaunos Therapeutics position peaked at $24K in Q3 2022.
82 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q4 2023.

Based on Meeder Asset Management's 13F filing for Q4 2023, filed 25 Jan 2024.